BOSTON--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced formation of its Scientific Advisory Board (SAB), comprised of top tier physicians and scientists from around the globe, spanning areas of expertise from chemistry, biology to medicine associated with the assessment and ultimate treatment of neurodegenerative diseases, such as Alzheimer’s Disease.

Professor Serge Gauthier of McGill University, Montreal, Quebec, Canada will serve as Chairperson of the Cerveau SAB, and will be joined by:

Jeffrey L. Evelhoch Ph.D., Retired, Vice-President, Head of Translational Biomarkers, Merck, PA,

Oskar Hansson M.D., Ph.D., Professor of Neurology at Lund University and consultant neurologist at Skane University Hospital, Sweden, Clinical Memory Research,

Richard Hargreaves Ph.D., Senior Vice President, Head Neuroscience Research and Early Development Bristol Myers Squibb, NJ,

Kanji Ishii, M.D. Leader, Team for Neuroimaging Research Tokyo Metropolitan Institute of Gerontology, Japan,

Keith Johnson M.D., Director, Molecular Neuroimaging, Massachusetts General Hospital, Neurologist, Memory Disorders Unit, Brigham and Women’s Hospital, Professor of Radiology, Harvard Medical School, MA.,

Eric M Reiman M.D. Executive Director, Banner Alzheimer’s Institute, Chief Executive Officer, Banner Research, Clinical Director of the Neurogenomics, Division at the Translational Genomics Research Institute, Professor of Psychiatry, University of Arizona and Director, Arizona Alzheimer’s Consortium, AZ,

Professor Christopher Rowe M.D., FRACP, FAANMS, Director, Australian Dementia Network University of Melbourne, Director of Molecular Imaging Research Austin Health, NHMRC Practitioner Fellow, Highly Cited Researcher 2019 (Top 1% in Neuroscience)

Koen Van Laere M.D., Ph.D., D.Sc., Head, Nuclear Medicine and Molecular Imaging, PET-MR Unit, Full Professor, Department of Imaging and Pathology, University Hospital Leuven-KU Leuven, Belgium

“We are delighted with the establishment of this new, incredibly powerful advisory board, and I am honored to serve as its chairperson,” said Serge Gauthier, C.M., C.Q., M.D., FRCPC, Director, Alzheimer Disease and Related Disorders Research Unit, McGill Center for Studies in Aging, Douglas Research Centre and Chairperson of the Cerveau SAB. “In our own work, and that of others on this SAB, the next generation Tau PET imaging biomarker, MK-6240, is proving invaluable to advancing our understanding of neurodegenerative disease. The formation of this SAB promises to catalyze breakthrough new advances in this exciting work,” added Gauthier, who is also Professor, Departments of Neurology and Neurosurgery, and Psychiatry at McGill University.

“Cerveau welcomes this opportunity to work with these world-class researchers to understand the application of MK-6240 and how it may benefit patients with Alzheimer’s Disease. We look forward to this collaboration making major strides toward addressing the unmet needs in neurodegenerative disease as well as providing future tools and technologies to support the development of disease modifying therapies,” said Rick Hiatt, President and CEO of Cerveau.

About Cerveau Technologies, Inc.

Cerveau's vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer's disease.